Collegium Pharmaceutical Gains Attention on ADHD Portfolio Strength After Q1 Beat KREF Q1 2026 Earnings Heavy Earnings Miss Despite Positive Stock Reaction Trainline Lifts FullYear Guidance for Second Time This Year